GlassScriptPhysician profile
Demetris A Green
NPI 1699973420
$25,757.96
in general payments reported to CMS, 2019-2025
45 companies · $3,695 in 2025
The $3,695 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,244 · 2020: $3,759 · 2021: $3,408 · 2022: $3,754 · 2023: $3,328 · 2024: $2,570 · 2025: $3,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,586 · Travel and Lodging: $6.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,586.35 |
| Travel and Lodging | $6.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,290.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,575.46 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,904.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,641.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $1,613.35 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,387.82 | 2019-2024 | Xifaxan, Trulance |
| Teva Pharmaceuticals USA, INC. | $1,349.72 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,156.52 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $971.34 | 2023-2025 | Repatha, Krystexxa, Otezla |
| Paratek Pharmaceuticals, INC. | $947.92 | 2020 | |
| Gilead Sciences, INC. | $925.65 | 2019-2025 | Yeztugo, Biktarvy, Epclusa |
| Vanda Pharmaceuticals INC. | $704.25 | 2019-2023 | Hetlioz |
| Janssen Pharmaceuticals, INC | $580.57 | 2019-2023 | Xarelto |
| Inspire Medical Systems, INC. | $580.23 | 2024-2025 | Inspire |
| Indivior INC. | $576.44 | 2019-2025 | Sublocade |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $536.63 | 2019-2022 | |
| Pfizer INC. | $532.60 | 2019-2025 | |
| Abbott Laboratories | $426.92 | 2021-2025 | Freestyle Libre 3 |
| Genzyme Corporation | $384.68 | 2023-2024 | |
| Astellas Pharma US INC | $355.47 | 2019-2025 | Veozah |
| Allergan, INC. | $337.49 | 2019-2020 | |
| Abbvie INC. | $332.74 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $267.60 | 2022-2023 | Ultomiris |
| Janssen Scientific Affairs, LLC | $231.45 | 2022-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $204.02 | 2020-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $191.14 | 2019-2023 | Steglatro, Belsomra, Lagevrio |
| Axsome Therapeutics, INC. | $171.29 | 2024-2025 | Auvelity |
| Mylan Specialty L.P. | $164.00 | 2022 | |
| Neurocrine Biosciences, INC. | $162.30 | 2019-2025 | |
| Cook Medical LLC | $160.72 | 2023 | Zilver Vena |
| Kowa Pharmaceuticals America, INC. | $150.73 | 2025 | Zoryve |
| Dexcom, INC. | $146.14 | 2019-2024 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $120.20 | 2025 | |
| Viiv Healthcare Company | $112.22 | 2025 | Apretude |
| Emd Serono, INC. | $108.54 | 2024 | Serostim |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2020 | |
| Exact Sciences Corporation | $85.67 | 2024-2025 | Cologuard Collection Kit |
| Eisai INC. | $65.21 | 2020-2022 | |
| Amarin Pharma, INC. | $64.47 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.67 | 2021-2022 | |
| Orexo US, INC. | $39.31 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $16.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.62 | 2023 | Quviviq |
| Janssen Biotech, INC. | $14.18 | 2023 | Symtuza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demetris Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.